- The trend backdrop is active with a 3-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
IBRX
NASDAQ
Week ended 09 Oct 2026
Weekly Investor Report
Immunitybio Inc · Healthcare · Biotechnology
Latest close
10.51 USD
2.2%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 32.3% above the Trend Line and sits at 81.7% of its 52-week range. The latest completed week returned 2.2%, after a 32.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 63/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: earnings are due in 21d.
Setup score
63
out of 100
Latest Close
10.51 USD
9 Oct 2026
1W Return
2.2%
latest completed week
4W Return
32.9%
short-term follow-through
12W Return
36.8%
quarterly tape
Trend Breadth
63.5%
33 of 52 weeks active
Volume Ratio
1.5x
vs 13-week average
- Next-week expectancy is negative at 42.62% based on similar historical setup states.
- 1 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
2.2%
Latest completed week; four-week move 32.9%.
Indicator stack
45/87
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 42.62%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
63/100 conviction; expected move 8.5%.
News sentiment
55/100
61 relevant articles in the latest sentiment read.
Event risk
21d
Next report is scheduled for 03 Nov 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 32.3% above the Trend Line and sits at 81.7% of its 52-week range. The latest completed week returned 2.2%, after a 32.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
18 Sep
25 Sep
2 Oct
9 Oct
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.6512-week average 0.53
12-week confirmation
Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.65Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers
No recent accumulation markers. 1 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 32.9% over four weeks, 36.8% over 12 weeks, and 345.3% over one year. The current trend has remained active for 3 consecutive weeks.
Performance by holding period
Active trend streak3 weeks
Active weeks in one year33
Trend breadth63.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.81Latest activity-pressure read.
Pressure change277.4%Four-week change in activity pressure.
Leadership45.63Latest relative-leadership reading.
RS change92.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Oct 2026
Financial statements through 30 Jun 2026
Field coverage 73%
Model confidence 72%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength59/100Blend of value, momentum, and quality. Underlying universe rank 42; rank 1 is best.
Value54/100Relative valuation strength. Underlying universe rank 47; rank 1 is best.
Quality52/100Profitability and accounting quality. Underlying universe rank 49; rank 1 is best.
Momentum54/100Medium-term price momentum. Underlying universe rank 47; rank 1 is best.
Growth54/100Revenue and earnings growth. Underlying universe rank 47; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 67.2x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -2.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 94.6% Gross profit retained from each unit of revenue.
- Operating margin
- -151.9% Operating profit retained from revenue.
- Free-cash-flow margin
- -174.0% Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 192.9% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -3.4% Net share repurchases relative to market value.
- Shareholder yield
- -3.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -3.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
IBRX shows volatility options pressure with a 63/100 conviction score, put-call volume ratio of 0.26, expected move of 8.5%, and Sharemaestro trend signal active.
Conviction63/100
Expected move8.5%
Put/call volume0.26
Insider activity7 / 9
7 acquisitions and 9 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment55/100
Weighted news tone is neutral across 61 relevant articles.
22 positive · 35 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings21dNext report is scheduled for 03 Nov 2026; event risk rises as the date approaches.
Options expected move8.5%Nearest-chain priced movement where available.
52-week drawdown-15.4%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
17 Apr
15 May
12 Jun
10 Jul
7 Aug
4 Sep
9 Oct
Weeks higher15 of 2611 weeks finished lower.
Best week+21.9%Week of 2 Oct.
Worst week-12.9%Week of 10 Jul.
Latest week+2.2%Week of 9 Oct.
Shape of recent returns
Strong gains8
Modest gains7
Flat weeks0
Modest losses4
Sharp losses7
Recent vol7.0%13-week weekly-return volatility.
Base vol21.2%52-week weekly-return volatility.
Up/down split26/25Count of positive and negative weeks in the 52-week window.
Average skew13.9% / -5.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average2.0%
Trend breadth63.0%
Trend63.0%active weekly trend signals
MD54.0%positive activity pressure
RS47.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank4 / 100
Group average-4.8%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD30.0%positive activity pressure
RS37.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape58/100
Trend, activity pressure, participation, and risk combine to a 58/100 tape read.
Indicator analysis53/100Latest 12-week confirmation: trend 6/12, activity pressure 2/12, relative leadership 12/12.
Activity pressure 0.65; 1 reversal markers Next-Week ExpectancyNegative 42.62%Next-week expectancy is negative with a 42.62% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors54/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 87; Small Cap Core rank 51 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options57/100Movement matters more than direction. Options do not give a clear directional confirmation of the stock trend.
2026-10-13 · Checks passed · Priced move ±8.5% Sentiment55/100Weighted news tone is neutral across 61 relevant articles.
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat Insiders7 / 97 acquisitions and 9 disposals in the latest 180-day insider tape.
Earnings21dNext report is scheduled for 03 Nov 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 9 Oct 2026 | 10.51 USD | 2.2% | 7.95 USD | 4.79 USD | 0.81 | 45.63 | 74.7M | On |
| 2 Oct 2026 | 10.28 USD | 21.9% | 7.87 USD | 4.73 USD | 0.37 | 45.75 | 89.6M | On |
| 25 Sep 2026 | 8.44 USD | -0.5% | 7.82 USD | 4.68 USD | -0.08 | 22.80 | 62.1M | On |
| 18 Sep 2026 | 8.48 USD | 7.2% | 7.87 USD | 4.63 USD | -0.20 | 29.36 | 64.9M | Off |
| 11 Sep 2026 | 7.91 USD | -2.1% | 7.87 USD | 4.59 USD | -0.46 | 23.65 | 38.5M | Off |
| 4 Sep 2026 | 8.08 USD | 0.4% | 7.81 USD | 4.55 USD | -0.56 | 27.41 | 30.2M | Off |
| 28 Aug 2026 | 8.05 USD | 3.3% | 7.74 USD | 4.51 USD | -0.57 | 29.37 | 47.0M | On |
| 21 Aug 2026 | 7.79 USD | 2.9% | 7.68 USD | 4.46 USD | -0.69 | 27.73 | 41.0M | Off |
| 14 Aug 2026 | 7.57 USD | -0.9% | 7.63 USD | 4.42 USD | -0.74 | 22.91 | 27.3M | Off |
| 7 Aug 2026 | 7.64 USD | 6.6% | 7.57 USD | 4.39 USD | -0.66 | 27.14 | 56.4M | Off |
| 31 Jul 2026 | 7.17 USD | 1.0% | 7.39 USD | 4.35 USD | -0.55 | 27.26 | 51.7M | On |
| 24 Jul 2026 | 7.10 USD | -7.6% | 7.22 USD | 4.32 USD | -0.25 | 28.56 | 39.4M | On |
| 17 Jul 2026 | 7.68 USD | -6.6% | 7.05 USD | 4.29 USD | 0.02 | 38.59 | 40.8M | On |
| 10 Jul 2026 | 8.22 USD | -12.9% | 6.87 USD | 4.26 USD | -0.07 | 44.30 | 58.7M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.